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Purpose: The aim of this analysis is to compare different tumour response 
criteria (TRC) after chemotherapy combined with bevacizumab in liver 
metastases from colorectal cancer (mCRC) to ascertain the best early 
prognostic indicator of response. 
Methods and Materials: 103 target liver metastases from 65 mCRC patients 
treated with chemoterapy plus bevacizumab were examined at the Istituto 
Oncologico Veneto IOV-IRCSS (March 2008-January 2013). All patients had 
baseline CT and at least one follow-up scan. Tumour response was 
retrospectively analyzed by two radiologists using RECIST1.1, modified Choi, 
and Chun morphologic criteria. Tumour response, classified as good (complete 
or partial response) or poor (stable or progressive disease), was compared 
with progression-free survival (PFS) at first follow-up (t1) and time of best 
response. Interobserver agreement and concordance between TRC were 
measured. 
Results: At t1, 32.31% showed a good response according to RECIST1.1 
(median PFS 11.1), 84.62% according to Choi (median PFS 10.8). These 
percentages rose to 49.23% (median PFS 12.1) and 87.69% (median PFS 
10.8), respectively, at the time of best response. According to Chun, 67.69% 
showed a good response at the time of best response (median PFS 10.8). The 
Choi criteria detected a higher proportion of good responders at t1, showing a 
better correlation with PFS; all methods correlated with PFS at the time of best 
response. 
Conclusion: The Choi criteria proved more consistent in the early detection of 
response in mCRC treated with chemotherapy plus bevacizumab, 
underscoring the importance of using these criteria in the early assessment of 
response to combined treatment.	
